stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. TNXP
    stockgist
    HomeTop MoversCompaniesConcepts
    TNXP logo

    Tonix Pharmaceuticals Holding Corp.

    TNXP
    NASDAQ
    Healthcare
    Biotechnology
    Chatham, NJ, US81 employeestonixpharma.com
    $13.91
    +0.23(1.6%)

    52W $12.03 – $61.57

    AI-generated from 10-K FY2025 filed Mar 11, 2026

    Tonix Pharmaceuticals Holding Corp.

    Revenue breakdown: Zembrace Symtouch (77%), Tosymra (16.9%), Tonmya (6.1%).

    $186MMkt Cap
    $21MRev TTM
    -$195MNI TTM
    -1.1xP/E TTM

    Latest Earnings

    10-K
    FY FY2025Mar 11, 2026

    Tonix Pharmaceuticals Holding Corp. (TNXP) reported FY 2025 product revenue of $13.1M, up 30% YoY from $10.1M in FY 2024, driven by $1.4M from TONMYA launch in November 2025, $9.3M from Zembrace SymTouch (+9% YoY), and $2.4M from Tosymra (+53% YoY). Cost of sales was $6.6M, yielding a gross margin of 50%, improved from negative gross profit in 2024 due...

    Read full analysisView SEC Filing

    What Changed Recently

    Regulation FDMar 30, 2026

    of this Current Report on Form 8-K, including Exhibits 99.01, 99.02 and 99.03 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Uni

    View filing →
    Regulation FDMar 25, 2026

    of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Ac

    View filing →
    Financial ResultsMar 12, 2026

    of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securit

    View filing →
    View all recent events →
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Mix3
    Zembrace Symtouch77%($18M)
    Tosymra16.9%($4M)
    Tonmya6.1%($1M)

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    FBRX logo
    FBRXForte Biosciences, Inc.
    $25.42+2.25%$318M-8.8
    AVTX logo
    AVTXAvalo Therapeutics, Inc.
    $17.79+6.54%$201M-2.3
    ELTX logo
    ELTXElicio Therapeutics, Inc.
    $10.64-0.19%$196M-4.2
    ELDN logo
    ELDNEledon Pharmaceuticals, I...
    $3.04+1.50%$183M-5.1
    NKTX logo
    NKTXNkarta, Inc.
    $2.31+5.71%$165M-1.6
    FATE logo
    FATEFate Therapeutics, Inc.
    $1.22-1.61%$142M-1.0
    IPHA logo
    IPHAInnate Pharma S.A.
    $1.37+1.48%$128M-2.1
    MIST logo
    MISTMilestone Pharmaceuticals...
    $1.38+5.34%$119M-1.7
    Company Profile
    CIK0001430306
    ISINUS8902608392
    CUSIP890260839
    Phone862 799 8599
    Address26 Main Street, Chatham, NJ, 07928, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice